Trexquant Investment’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-68,054
| Closed | -$2.05M | – | 2229 |
|
|
2026
Q1 | $2.05M | Buy |
+68,054
| New | +$2.19M | 0.01% | 986 |
|
|
2025
Q4 | – | Sell |
-265,316
| Closed | -$5.36M | – | 1928 |
|
|
2025
Q3 | $5.36M | Buy |
+265,316
| New | +$4.66M | 0.06% | 526 |
|
|
2025
Q2 | – | Sell |
-203,909
| Closed | -$3.13M | – | 1876 |
|
|
2025
Q1 | $3.13M | Buy |
203,909
+108,986
| +115% | +$1.95M | 0.04% | 701 |
|
|
2024
Q4 | $2.09M | Buy |
+94,923
| New | +$1.73M | 0.02% | 850 |
|
|
2024
Q3 | – | Sell |
-317,446
| Closed | -$5.16M | – | 1854 |
|
|
2024
Q2 | $5.16M | Sell |
317,446
-61,887
| -16% | -$953K | 0.08% | 396 |
|
|
2024
Q1 | $5.35M | Buy |
+379,333
| New | +$4.78M | 0.11% | 274 |
|
|
2023
Q2 | – | Sell |
-276,500
| Closed | -$2.45M | – | 1800 |
|
|
2023
Q1 | $2.45M | Buy |
+276,500
| New | +$2.73M | 0.07% | 390 |
|
|
2022
Q4 | – | Sell |
-254,152
| Closed | -$2.05M | – | 1729 |
|
|
2022
Q3 | $2.05M | Buy |
254,152
+132,358
| +109% | +$1.17M | 0.07% | 352 |
|
|
2022
Q2 | $916K | Buy |
121,794
+105,551
| +650% | +$920K | 0.04% | 551 |
|
|
2022
Q1 | $153K | Buy |
+16,243
| New | +$136K | 0.01% | 1246 |
|
|
2021
Q3 | – | Sell |
-136,109
| Closed | -$1.35M | – | 1485 |
|
|
2021
Q2 | $1.35M | Buy |
136,109
+124,753
| +1,099% | +$1.32M | 0.11% | 243 |
|
|
2021
Q1 | $131K | Buy |
+11,356
| New | +$130K | 0.01% | 1032 |
|
|
2020
Q2 | – | Sell |
-267,151
| Closed | -$2.4M | – | 1474 |
|
|
2020
Q1 | $2.4M | Buy |
+267,151
| New | +$2.74M | 0.17% | 161 |
|
|
2019
Q1 | – | Sell |
-233,335
| Closed | -$3.6M | – | 1311 |
|
|
2018
Q4 | $3.6M | Buy |
+233,335
| New | +$4.78M | 0.22% | 129 |
|
|
2018
Q3 | – | Sell |
-77,691
| Closed | -$1.89M | – | 1187 |
|
|
2018
Q2 | $1.89M | Buy |
+77,691
| New | +$1.58M | 0.13% | 239 |
|
|
2016
Q4 | – | Sell |
-11,800
| Closed | -$543K | – | 1129 |
|
|
2016
Q3 | $543K | Sell |
11,800
-32,600
| -73% | -$1.7M | 0.12% | 287 |
|
|
2016
Q2 | $2.23M | Buy |
44,400
+5,507
| +14% | +$293K | 0.29% | 78 |
|
|
2016
Q1 | $2.08M | Buy |
+38,893
| New | +$2.28M | 0.24% | 96 |
|
|
2015
Q4 | – | Sell |
-26,500
| Closed | -$1.5M | – | 1253 |
|
|
2015
Q3 | $1.5M | Buy |
26,500
+700
| +3% | +$45.4K | 0.13% | 251 |
|
|
2015
Q2 | $1.52M | Buy |
+25,800
| New | +$1.59M | 0.17% | 185 |
|
|
2015
Q1 | – | Sell |
-9,500
| Closed | -$545K | – | 1179 |
|
|
2014
Q4 | $545K | Buy |
+9,500
| New | +$529K | 0.1% | 429 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Trexquant Investment's TEVA Position: Q2 2026 in Review
Trexquant Investment sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 68,054 shares — an estimated $2.05M sold.
Trexquant Investment first reported a position in TEVA in Q4 2014 and held it in 21 quarters. The position peaked at $5.36M in Q3 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Trexquant Investment reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Trexquant Investment sold 68,054 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.05M.
- Trexquant Investment first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 21 quarters.
- Trexquant Investment's Teva Pharmaceuticals position peaked at $5.36M in Q3 2025.
- 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.